Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.124.268217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Adriana Amerein und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, Octreotide, Receptors, Peptide. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with advanced meningioma. Recently, intraarterial application of the radiolabeled somatostatin receptor agonists has been introduced as an alternative to standard intravenous administration. In this study, we assessed the safety and efficacy of intraarterial PRRT in patients with advanced, progressive meningioma.
Methods
Patients with advanced, progressive meningioma underwent intraarterial PRRT with [177Lu]Lu-HA-DOTATATE. The safety of PRRT was evaluated according to the Common Terminology Criteria for Adverse Events version 5.0. Treatment response was assessed according to the proposed Response Assessment in Neuro-Oncology criteria for meningiomas and somatostatin receptor-directed PET/CT.
Results
Thirteen patients (8 women, 5 men; mean age, 65 ± 13 y) with advanced meningioma underwent 1-4 cycles (median, 4 cycles) of intraarterial PRRT with [177Lu]Lu-HA-DOTATATE (mean activity per cycle, 7,428 ± 237 MBq; range, 6,000-7,700 MBq). Treatment was well tolerated with mainly grade 1-2 hematologic toxicity. Ten of 13 patients showed radiologic disease control at follow-up after therapy (1/10 complete remission, 1/10 partial remission, 8/10 stable disease), and 9 of 13 patients showed good control of clinical symptoms.
Conclusion
Intraarterial PRRT in patients with advanced meningioma is feasible and safe. It may result in improved radiologic and clinical disease control compared with intravenous PRRT. Further research to validate these initial findings and to investigate long-term outcomes is highly warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Diagnostic and Interventional Neuroradiology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Medical Physics, University Hospital Augsburg, Augsburg, Germany.
- Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands; and.
- Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany; constantin.lapa@uk-augsburg.de.
Zitieren
APA
Amerein, A., Maurer, C., Kircher, M., Gäble, A., Krebold, A., Rinscheid, A., Viering, O., Pfob, C. H., Bundschuh, R. A., Behrens, L., Braat, A. J., Berlis, A., & Lapa, C. (2024). Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268217
Vancouver
Amerein A, Maurer C, Kircher M, Gäble A, Krebold A, Rinscheid A, et al. Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.268217
BibTeX
@article{Amerein2024,
author = {Amerein, Adriana and Maurer, Christoph and Kircher, Malte and Gäble, Alexander and Krebold, Anne and Rinscheid, Andreas and Viering, Oliver and Pfob, Christian H and Bundschuh, Ralph A and Behrens, Lars and Braat, Arthur Jat and Berlis, Ansgar and Lapa, Constantin},
title = {Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.124.268217}
}
EUVIMED